DOCSLIB.ORG

Interferon Regulatory Transcription Factors Are Constitutively Expressed and Spatially Regulated in the Mouse Lens

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interferon Regulatory Transcription Factors Are Constitutively Expressed and Spatially Regulated in the Mouse Lens Developmental Biology 210, 44–55 (1999) Article ID dbio.1999.9267, available online at http://www.idealibrary.com on Interferon Regulatory Transcription Factors Are Constitutively Expressed and Spatially Regulated in the Mouse Lens Wenmei Li,* Chandrasekharam N. Nagineni,* Bassey Efiok,† Ana B. Chepelinsky,‡ and Charles E. Egwuagu*,1 *Laboratory of Immunology and ‡Laboratory of Molecular & Developmental Biology, National Eye Institute, and †Laboratory of Molecular Hematology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 Interferon regulatory factors (IRFs) are a family of transcription factors involved in regulation of cell growth and immunological responses. Nine IRFs have been described and they are expressed in a variety of cells, except for ICSBP and LSIRF/Pip, which are thought to be expressed exclusively in immune cells. Here, we show that IRF-1, IRF-2, ICSBP, and LSIRF/Pip are constitutively expressed in the mouse lens. These IRFs are present in both the cytoplasm and the nuclei of lens cells. However, the nuclear and cytoplasmic proteins exhibit distinct mobilities on SDS/PAGE. We further show that in the developing mouse lens, IRF-1 and IRF-2 are expressed at high levels in differentiated lens fiber cells with very low and barely detectable levels in undifferentiated lens epithelial cells. Although the level of ICSBP expression is very low in the normal mouse lens, in transgenic mice with constitutive expression of interferon g in the lens, its level is markedly elevated and ICSBP expression is detected exclusively in the nuclei of undifferentiated lens cells. Taken together, our data suggest that expression of IRF transcription factors is spatially regulated in the lens and that distinct IRFs may contribute to differential gene regulation in the epithelial and fiber compartments of the vertebrate lens. Key Words: IFNg; ICSBP; LSIRF/Pip; IRF-1; IRF-2; STAT1; lens differentiation. INTRODUCTION called STATs (signal transducers and activators of tran- scription) (Darnell, 1997). Phosphorylated STATs form Interferons (IFNs) are multifunctional cytokines induced homo- or heterodimers that translocate to the nucleus in almost all vertebrate cells in response to infection or where they bind to well-defined DNA sequences called immunological stimuli. There are two main types: Type 1 GAS (gamma IFN activation site) or ISREs (IFN-stimulated IFN comprises leukocyte (IFNa) and fibroblast (IFNb) IFNs response elements) and activate transcription of genes cod- while Type 2 or immune IFN is IFNg (Vilcek and Sen, ing for members of the interferon regulatory factors (IRFs) 1996). Although the two types of IFNs differ in the cell family of transcription factors (Decker et al., 1997; Boehm surface receptors they bind to and their physiological in- et al., 1997). ducers, their biological activities are mediated through IRFs interact with ISRE motifs in the promoters of activation of the JAK/STAT signaling pathway (Schindler IFN-regulatable genes and they mediate transcriptional and Darnell, 1995). Interaction of IFNs with their receptors activation or repression of these genes. Ten members of the leads to activation of protein tyrosine kinases, JAK1, JAK2, IRF family have been identified and they include ICSBP, or Tyk2, which in turn phosphorylate and activate mem- ISGF3g/p48, IRF-1, IRF-2, IRF-3, IRF-4/LSIRF/Pip/ICSAT, bers of a family of latent cytoplasmic transcription factors IRF-5, IRF-6, IRF-7, and vIRF (Nguyen et al., 1997). IRFs differ in the range of cell types they are normally expressed 1 To whom correspondence should be addressed at the Labora- in, their physiological inducers, and the biological processes tory of Immunology, National Eye Institute, National Institutes of they affect (Nguyen et al., 1997). With the recent demon- Health, 10/10N116, 10 Center Drive MCS 1858, Bethesda, MD stration of a virally encoded homologue of cellular IRFs 20892. Fax: (301) 480-3914. E-mail: [email protected]. (Moore et al., 1996), it is likely that more IRFs will be 44 0012-1606/99 Differential Expression of IRFs in the Lens 45 identified and previously described members would be and Ophthalmology Resolution on the Use of Animals in Re- found to possess new functions. search. IRF-1 and IRF-2 are the best characterized members of this family and were initially identified as regulators of the Cell Culture and IFNg Treatment IFN system (Miyamoto et al., 1988; Harada et al., 1989). They have subsequently been shown to be key factors in the The murine lens epithelial cell line, aTN4-1 (Yamada et al., regulation of cell growth through their effects on the cell 1990), kindly provided by Dr. Paul Russell (NEI, NIH, Bethesda, cycle (Taniguchi et al., 1995; Vaughan et al., 1997). IRF-1 is MD), was grown in Dulbecco’s modified Eagle’s medium supple- mented with 10% fetal bovine serum, 2 mM glutamine, penicillin thought to function in a manner analogous to the tumor (100 U/ml), and streptomycin (100 mg/ml). The CRLE 2 and 1AMLE suppressor p53, activating a set of genes whose products are 6 mouse epithelial cell lines (Sax et al., 1995), kind gifts from Dr. required for negative regulation of cell growth. On the other Christina M. Sax (NEI, NIH, Bethesda, MD), were propagated in hand, IRF-2, which shares significant sequence similarity to minimum essential medium supplemented with 5% rabbit serum, IRF-1 within the DNA binding domain, represses IRF1- 5% fetal bovine serum, 2 mM glutamine, penicillin (100 U/ml) and regulatable genes (Taniguchi, 1997). In contrast to IRF-1 and streptomycin (100 mg/ml). The cells were treated with murine IRF-2 that are expressed in a variety of cell types, two IRF recombinant IFNg (Life Technologies, Gaithersburg, MD) at a members, ICSBP (interferon consensus sequence binding concentration of 100 U/ml for2hat37°C, 5% CO2. Some cells protein) (Driggers et al., 1990) and LSIRF/Pip (lymphoid- were treated with medium containing the protein synthesis inhib- m specific IRF or Pu.1 interaction partner) (Eisenbeis et al., itor, cycloheximide (CHX) (Sigma, St. Louis, MO) at 35 g/ml for 30 min followed by addition of IFNg and incubation for 2 h. 1995; Matsuyama et al., 1995; Yamagata et al., 1996) are thought to be expressed exclusively in cells of macrophage and lymphocyte lineages. Constitutive expression of ICSBP Reverse-Transcribed Polymerase Chain Reaction is thought to be limited to B lymphocytes (Driggers et al., (RT-PCR) 1990; Politis et al., 1994; Nelson et al., 1996). However, Total RNA was isolated from 6-week-old WT or TR mouse lenses transcription of the ICSBP gene can be induced in T cells or from lens cell lines by a modification of the phenol–guanidine and macrophages by either IFNg or antigenic stimulation isothiocyanate single-step method (Chomczynski and Sacchi, 1987) as (Politis et al., 1994; Nelson et al., 1996). LSIRF/Pip expres- described for the TRIzol Reagent (Life Technologies). Lenses were sion is thought to be restricted to cells of the T and B carefully dissected and washed before RNA isolation to avoid any lymphocyte lineages. Mice with a null mutation for the possible contamination by other tissues. All RNA samples were ICSBP or LSIRF/Pip gene develop myelogenous leukemia- digested with RNase-free DNase 1 (Life Technologies) for 30 min and like syndrome (Holtschke et al., 1996) or developmental purified by phenol–chloroform extraction and precipitation in 0.4 M m defects in lymphocyte maturation (Mittrucker et al., 1997), LiCl. cDNA synthesis was performed at 42°C for 1 h with 10 gof total RNA, 0.3 mg oligo(dT) and 1000 U Superscript Reverse respectively. Taken together, these observations have pro- (12-16) Transcriptase II (Life Technologies) in a final volume of 50 ml. For each vided support for the notion that LSIRF/Pip and ICSBP are RNA preparation, a negative control reaction was performed without lymphoid-specific IRFs. reverse transcriptase. After purification of the cDNA by LiCl precipi- We have previously reported the generation of transgenic tation, hot-start PCR assays were performed with AmpliTaq Gold mice with targeted ectopic expression of IFNg in the lens DNA polymerase (Perkin–Elmer, Foster City, CA). Samples were under the direction of the aA-crystallin promoter (Egwuagu incubated at 95°C for 10 min to activate the AmpliTaq Gold and et al., 1994a,b). In these mice, eye development is inhibited amplification was carried out for 25 cycles at 94°C for 45 s, 63°C for and the developmental fate of cells destined to become lens 45 s, and 72°C for 1 min. This was followed by a final 10-min fiber cells is altered. In the present study, we show that extension at 72°C. All the primer pairs used for PCR amplifications abnormal lens differentiation observed in the IFNg trans- spanned at least one intron, making it possible to distinguish between amplification products derived from cDNA and those resulting from genic mice may derive in part from perturbations in the any contaminating genomic DNA templates. The sequences of the levels of IRF factors in the lens. We also show for the first PCR primers used are for mouse b-actin, 59-GTGGGCC- time that ICSBP, LSIRF/Pip, IRF-1, and IRF-2 are constitu- GCTCTAGGCACCAA-39 and 59-TCGTTGCCAATAGT- tively expressed in the normal mouse lens and that expres- GATGACTTGGC-39 (Alonso et al., 1986); for mouse G3PDH, sion of these IRFs is spatially regulated in the developing 59-TGAAGGTCGGTGTGAACGGATTTGGC-39 and 59- mouse lens. CATGTAGGCCATGAGGTCCACCAC-39 (Sabath et al., 1990); for mouse IRF-1, 59-TGAGACCCTGGCTAGAGATGC-39 and 59- ACTCAGAGAGACTGCTGCTGACGAC-39 (Pine et al., 1990); for mouse IRF-2, 59-AGCATCAACCAGGAATAGATAAAC-39 and 59- MATERIALS AND METHODS ATAGGTGTTCCGTGTCCCCAT-39 (Harada et al., 1989); for mouse ICSBP, 59-GCTGCGGCAGTGGCTGATCGAACAGATCG-39 and Animals 59-AGTGGCAGGCC TGCACTGGGCTGCTG-39 (Driggers et al., 1990).
Load more

Recommended publications
  • IFN-Α Wakes up Sleeping Hematopoietic Stem Cells
    NEWS AND VIEWS calcium consumption does not seem to have without increasing the risk of coronary heart 7. Aoki, K. et al. Ann. Epidemiol. 15, 598–606 (2005). such an effect. How to optimize calcium sup- disease, which has been associated with cal- 8. Langhans, N. et al. Gastroenterology 112, 280–286 13 plements for human health deserves further cium supplementation . (1997). investigation. 9. Recker, R.R. N. Engl. J. Med. 313, 70–73 (1985). 10. Yang, Y.-X. et al. J. Am. Med. Assoc. , 2947– Maybe it’s time to determine whether low- 1. Zaidi, M. Nat. Med. 13, 791–801 (2007). 296 2. Del Fattore, A. et al. Bone 42, 19–29 (2008). 2953 (2006). fat milk–based drinks taken as an alternative 3. Sobacchi, C. et al. Hum. Mol. Genet. 10, 1767–1773 11. Collazo-Clavell, M.L., Jimenez, A., Hodgson, S.F. & to the soda so frequently consumed, especially (2001). Sarr, M.G. Endocr. Pract. 10, 195–198 (2004). 4. Amling, M. et al. Nat. Med. 15, 674–681 (2009). 12. Bo-Linn, G.W. et al. J. Clin. Invest. 73, 640–647 during the early adolescent years, can attain 5. Straub, D.A. Nutr. Clin. Pract. 22, 286–296 (2007). (1984). the noble goal of keeping bones healthy— 6. Teitelbaum, S.L. Science 289, 1504–1508 (2000). 13. Bolland, M.J. BMJ 336, 262–266 (2008). IFN-α wakes up sleeping hematopoietic stem cells Emmanuelle Passegué & Patricia Ernst The cytokine interferon-α stimulates the turnover and proliferation of hematopoietic cells in vivo (pages 696–700).
    [Show full text]
  • Transcription Factor IRF4 Drives Dendritic Cells to Promote Th2 Differentiation
    ARTICLE Received 30 May 2013 | Accepted 21 Nov 2013 | Published 20 Dec 2013 DOI: 10.1038/ncomms3990 Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation Jesse W. Williams1, Melissa Y. Tjota2,3, Bryan S. Clay2, Bryan Vander Lugt4, Hozefa S. Bandukwala2, Cara L. Hrusch5, Donna C. Decker5, Kelly M. Blaine5, Bethany R. Fixsen5, Harinder Singh4, Roger Sciammas6 & Anne I. Sperling1,2,5 Atopic asthma is an inflammatory pulmonary disease associated with Th2 adaptive immune responses triggered by innocuous antigens. While dendritic cells (DCs) are known to shape the adaptive immune response, the mechanisms by which DCs promote Th2 differentiation remain elusive. Herein we demonstrate that Th2-promoting stimuli induce DC expression of IRF4. Mice with conditional deletion of Irf4 in DCs show a dramatic defect in Th2-type lung inflammation, yet retain the ability to elicit pulmonary Th1 antiviral responses. Using loss- and gain-of-function analysis, we demonstrate that Th2 differentiation is dependent on IRF4 expression in DCs. Finally, IRF4 directly targets and activates the Il-10 and Il-33 genes in DCs. Reconstitution with exogenous IL-10 and IL-33 recovers the ability of Irf4-deficient DCs to promote Th2 differentiation. These findings reveal a regulatory module in DCs by which IRF4 modulates IL-10 and IL-33 cytokine production to specifically promote Th2 differentiation and inflammation. 1 Committee on Molecular Pathogenesis and Molecular Medicine, University of Chicago, 924 E. 57th Street, Chicago, Illinois 60637 USA. 2 Committee on Immunology, University of Chicago, 924 E. 57th Street, Chicago, Illinois 60637 USA. 3 Medical Scientist Training Program, University of Chicago, 924 E.
    [Show full text]
  • CDP/Cut Is the DNA-Binding Subunit of Histone Gene Transcription Cell
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 11516-11521, October 1996 Biochemistry CDP/cut is the DNA-binding subunit of histone gene transcription factor HiNF-D: A mechanism for gene regulation at the G1/S phase cell cycle transition point independent of transcription factor E2F (proliferation/gene expression/cyclin-dependent kinase/tumor suppressor) A. J. VAN WIJNEN*, M. F. vAN GURP*, M. C. DE RIDDER*, C. TUFARELLIt, T. J. LAST*, M. BIRNBAUM*, P. S. VAUGHAN*, A. GIORDANOt, W. KREK§, E. J. NEUFELDt, J. L. STEIN*, AND G. S. STEIN* *Department of Cell Biology, University of Massachusetts Medical School and Cancer Center, 55 Lake Avenue North, Worcester, MA 01655; tDivision of Hematology, Enders 720, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115; tInstitute for Cancer Research and Molecular Medicine, Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, PA 19107; and §Friedrich-Miescher Institut, Postfach 2543, CH-4002 Basel, Switzerland Communicated by Sheldon Penman, Massachusetts Institute of Technology, Cambridge, MA, June 26, 1996 (received for review June 5, 1996) ABSTRACT Transcription of the genes for the human. 2/pl3O, and p107), CDKs, and cyclins A and E (14-17). histone proteins H4, H3,.H2A, H2B, and Hi is activated at the Variation in the composition of E2F containing multiprotein G1/S phase transition of the cell cycle. We have previously complexes may be functionally relevant for the timing and shown that the promoter complex HiNF-D, which interacts extent to which cell cycle controlled genes are activated or with cell cycle control elements in multiple histone genes, repressed. contains the key cell cycle factors cyclin A, CDC2, and a Expression of the genes for the histone proteins H4, H3, retinoblastoma (pRB) protein-related protein.
    [Show full text]
  • Irf1) Signaling Regulates Apoptosis and Autophagy to Determine Endocrine Responsiveness and Cell Fate in Human Breast Cancer
    INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER A Dissertation Submitted to the Faculty of the Graduate School of Arts and Sciences of Georgetown University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Physiology & Biophysics By Jessica L. Roberts, B.S. Washington, DC September 27, 2013 Copyright 2013 by Jessica L. Roberts All Rights Reserved ii INTERFERON REGULATORY FACTOR-1 (IRF1) SIGNALING REGULATES APOPTOSIS AND AUTOPHAGY TO DETERMINE ENDOCRINE RESPONSIVENESS AND CELL FATE IN HUMAN BREAST CANCER Jessica L. Roberts, B.S. Thesis Advisor: Robert Clarke, Ph.D. ABSTRACT Interferon regulatory factor-1 (IRF1) is a nuclear transcription factor and pivotal regulator of cell fate in cancer cells. While IRF1 is known to possess tumor suppressive activities, the role of IRF1 in mediating apoptosis and autophagy in breast cancer is largely unknown. Here, we show that IRF1 inhibits antiapoptotic B-cell lymphoma 2 (BCL2) protein expression, whose overexpression often contributes to antiestrogen resistance. We proposed that directly targeting the antiapoptotic BCL2 members with GX15-070 (GX; obatoclax), a BH3-mimetic currently in clinical development, would be an attractive strategy to overcome antiestrogen resistance in some breast cancers. Inhibition of BCL2 activity, through treatment with GX, was more effective in reducing the cell density of antiestrogen resistant breast cancer cells versus sensitive cells, and this increased sensitivity correlated with an accumulation of autophagic vacuoles. While GX treatment promoted autophagic vacuole and autolysosome formation, p62/SQSTM1, a marker for autophagic degradation, levels accumulated.
    [Show full text]
  • In Vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 In vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3 4 Clarissa S. Santoso1, Zhaorong Li2, Jaice T. Rottenberg1, Xing Liu1, Vivian X. Shen1, Juan I. 5 Fuxman Bass1,2 6 7 1Department of Biology, Boston University, Boston, MA 02215, USA; 2Bioinformatics Program, 8 Boston University, Boston, MA 02215, USA 9 10 Corresponding author: 11 Juan I. Fuxman Bass 12 Boston University 13 5 Cummington Mall 14 Boston, MA 02215 15 Email: [email protected] 16 Phone: 617-353-2448 17 18 Classification: Biological Sciences 19 20 Keywords: COVID-19, cytokine release syndrome, cytokine storm, drug repurposing, 21 transcriptional regulators 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 22 Abstract 23 Treatment of the cytokine release syndrome (CRS) has become an important part of rescuing 24 hospitalized COVID-19 patients. Here, we systematically explored the transcriptional regulators 25 of inflammatory cytokines involved in the COVID-19 CRS to identify candidate transcription 26 factors (TFs) for therapeutic targeting using approved drugs.
    [Show full text]
  • Differential and Overlapping Immune Programs Regulated by IRF3 and IRF5 in Plasmacytoid Dendritic Cells
    Differential and Overlapping Immune Programs Regulated by IRF3 and IRF5 in Plasmacytoid Dendritic Cells This information is current as Kwan T. Chow, Courtney Wilkins, Miwako Narita, Richard of September 28, 2021. Green, Megan Knoll, Yueh-Ming Loo and Michael Gale, Jr. J Immunol published online 8 October 2018 http://www.jimmunol.org/content/early/2018/10/05/jimmun ol.1800221 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2018/10/05/jimmunol.180022 Material 1.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2018 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published October 8, 2018, doi:10.4049/jimmunol.1800221 The Journal of Immunology Differential and Overlapping Immune Programs Regulated by IRF3 and IRF5 in Plasmacytoid Dendritic Cells Kwan T. Chow,*,† Courtney Wilkins,* Miwako Narita,‡ Richard Green,* Megan Knoll,* Yueh-Ming Loo,* and Michael Gale, Jr.* We examined the signaling pathways and cell type–specific responses of IFN regulatory factor (IRF) 5, an immune-regulatory transcription factor.
    [Show full text]
  • Rnaseq Analysis Identifies Non-Canonical Role of STAT2 And
    bioRxiv preprint doi: https://doi.org/10.1101/273623; this version posted February 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 RNASeq analysis identifies non-canonical role of STAT2 and IRF9 in 2 the regulation of a STAT1-independent antiviral and 3 immunoregulatory transcriptional program induced by IFNβ and 4 TNFα 5 6 Mélissa K. Mariani1, Pouria Dasmeh2,3, Audray Fortin1, Mario Kalamujic1, Elise Caron1, 7 Alexander N. Harrison1,4 Sandra Cervantes-Ortiz1,5, Espérance Mukawera1, Adrian W.R. 8 Serohijos2,3 and Nathalie Grandvaux1,2* 9 10 1 CRCHUM - Centre Hospitalier de l’Université de Montréal, Québec, Canada 11 2 Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal, 12 Qc, Canada. 13 3 Centre Robert Cedergren en Bioinformatique et Génomique, Université de Montréal, Qc, Canada 14 4 Department of Microbiology and Immunology, McGill University, Qc, Canada 15 5 Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, Université de 16 Montréal, Qc, Canada 17 18 * Correspondence: 19 Corresponding Author 20 [email protected] 21 22 Keywords: Interferon β, TNFα, STAT1, STAT2, IRF9, antiviral, 23 24 Running title: STAT1-independent transcriptional response to IFNβ+TNFα 25 26 27 1 bioRxiv preprint doi: https://doi.org/10.1101/273623; this version posted February 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Expression Profiling Associates Blood and Brain Glucocorticoid Receptor
    Expression profiling associates blood and brain SEE COMMENTARY glucocorticoid receptor signaling with trauma-related individual differences in both sexes Nikolaos P. Daskalakisa,b,1, Hagit Cohenc, Guiqing Caia,d, Joseph D. Buxbauma,d,e, and Rachel Yehudaa,b,e Departments of aPsychiatry, dGenetics and Genomic Sciences, and eNeuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bMental Health Patient Care Center, James J. Peters Veterans Affairs Medical Center, Bronx, NY 10468; and cAnxiety and Stress Research Unit, Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84170, Israel Edited by Bruce S. McEwen, The Rockefeller University, New York, NY, and approved July 14, 2014 (received for review February 7, 2014) Delineating the molecular basis of individual differences in the stress response to stress (4, 5). The emergence of system- and genome- response is critical to understanding the pathophysiology and treat- wide approaches permits the opportunity for unbiased identifi- ment of posttraumatic stress disorder (PTSD). In this study, 7 d after cation of novel pathways. Because PTSD is more prevalent in predator-scent-stress (PSS) exposure, male and female rats were women than men (1), and sex is a potential source of response classified into vulnerable (i.e., “PTSD-like”) and resilient (i.e., minimally variation to trauma in both animals (6) and humans (7), it is also affected) phenotypes on the basis of their performance on a variety of critical to include both sexes in such studies. behavioral measures. Genome-wide expression profiling in blood and In the present study, PSS-exposed male and female rats were two limbic brain regions (amygdala and hippocampus), followed by behaviorally tested in EPM and ASR tests a week after PSS and divided in EBR and MBR groups [at this point, the behavioral quantitative PCR validation, was performed in these two groups of response of the rats is stable in terms of prevalence of EBRs vs.
    [Show full text]
  • Sirna Targeting the IRF2 Transcription Factor Inhibits Leukaemic Cell Growth
    175-183 9/6/08 16:54 Page 175 INTERNATIONAL JOURNAL OF ONCOLOGY 33: 175-183, 2008 175 siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth AILYN CHOO1, PATRICIA PALLADINETTI1, TIFFANY HOLMES2, SHREERUPA BASU2, SYLVIE SHEN1, RICHARD B. LOCK1, TRACEY A. O'BRIEN2, GEOFF SYMONDS1 and ALLA DOLNIKOV1,2 1Children's Cancer Institute Australia for Medical Research; 2Sydney Cord & Marrow Transplant Facility, Sydney Children's Hospital, High Street, Randwick NSW 2031, Australia Received January 11, 2008; Accepted February 27, 2008 Abstract. Interferon regulatory factor (IRF) 1 and its functional mechanisms or transcriptional regulators thereby directly antagonist IRF2 were originally discovered as transcription interfering with haematopoietic cell growth and differentiation factors that regulate the interferon-ß gene. Control of cell (1). growth has led to the definition of IRF1 as a tumour suppressor Mutations that create constitutively active Ras proteins gene and IRF2 as an oncogene. Clinically, approximately are among the most frequently detected genetic alterations in 70% of cases of acute myeloid leukaemia demonstrate dys- human leukaemia (2), occurring in approximately 30% of regulated expression of IRF1 and/or IRF2. Our previous AML cases (3). While frequently activated in haematopoietic studies have shown that human leukaemic TF-1 cells exhibit malignancies, the manner in which Ras activation contributes abnormally high expression of both IRF1 and IRF2, the latter to human leukaemia is not well understood. The Ras protein acting to abrogate IRF1 tumour suppression, making these has a crucial role in many haematopoietic regulatory processes cells ideal for analysis of down-regulation of IRF2 expression. and has been the target of many therapeutic approaches (3,4).
    [Show full text]
  • Frequent Loss of IRF2 in Cancers Leads to Immune Evasion Through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
    Published August 30, 2019, doi:10.4049/jimmunol.1900475 The Journal of Immunology Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression Barry A. Kriegsman,* Pranitha Vangala,† Benjamin J. Chen,* Paul Meraner,‡ Abraham L. Brass,‡,x,{ Manuel Garber,† and Kenneth L. Rock* To arise and progress, cancers need to evade immune elimination. Consequently, progressing tumors are often MHC class I (MHC-I) low and express immune inhibitory molecules, such as PD-L1, which allows them to avoid the main antitumor host defense, CD8+ T cells. The molecular mechanisms that led to these alterations were incompletely understood. In this study, we identify loss of the transcription factor IRF2 as a frequent underlying mechanism that leads to a tumor immune evasion phenotype in both humans and mice. We identified IRF2 in a CRISPR-based forward genetic screen for genes that controlled MHC-I Ag presentation in HeLa cells. We then found that many primary human cancers, including lung, colon, breast, prostate, and others, frequently downregulated IRF2. Although IRF2 is generally known as a transcriptional repressor, we found that it was a transcriptional activator of many key components of the MHC-I pathway, including immunoproteasomes, TAP, and ERAP1, whose transcrip- tional control was previously poorly understood. Upon loss of IRF2, cytosol-to–endoplasmic reticulum peptide transport and N-terminal peptide trimming become rate limiting for Ag presentation. In addition, we found that IRF2 is a repressor of PD-L1. Thus, by downregulating a single nonessential gene, tumors become harder to see (reduced Ag presentation), more inhibitory (increased checkpoint inhibitor), and less susceptible to being killed by CD8+ T cells.
    [Show full text]
  • 1 Type I Interferon Transcriptional Network Regulates Expression Of
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.30.362947; this version posted October 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Type I Interferon Transcriptional Network Regulates Expression of Coinhibitory Receptors in Human T cells Tomokazu S. Sumida*1, Shai Dulberg2*, Jonas Schupp3*, Helen A. Stillwell1, Pierre-Paul Axisa1, Michela Comi1, Matthew Lincoln1, Avraham Unterman3, Naftali Kaminski3, Asaf Madi2,4, Vijay K. Kuchroo4,5,†, David A. Hafler1,5,† 1Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA. 2 Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3Section of Pulmonary, Critical Care and Sleep Medicine Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. 4 Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA. 5Broad Institute of MIT and Harvard, Cambridge, MA, USA. *Equal Contributions † Correspondence to Drs. Vijay Kuchroo ([email protected]) or David Hafler ([email protected]) 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.10.30.362947; this version posted October 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
    [Show full text]
  • IRF2BP2 Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia
    pharmaceuticals Case Report IRF2BP2 Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia Maaria Palmroth 1 , Hanna Viskari 2,3, Mikko R. J. Seppänen 4, Salla Keskitalo 5, Anniina Virtanen 1, Markku Varjosalo 5, Olli Silvennoinen 1,6,7 and Pia Isomäki 1,8,* 1 Molecular Immunology Group, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland; maaria.palmroth@tuni.fi (M.P.); anniina.t.virtanen@tuni.fi (A.V.); olli.silvennoinen@tuni.fi (O.S.) 2 Department of Internal Medicines, Tampere University Hospital, 33520 Tampere, Finland; hanna.viskari@pshp.fi 3 Faculty of Medicine and Life Sciences, Tampere University, 33520 Tampere, Finland 4 Rare Disease and Pediatric Research Centers, Children’s Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland; mikko.seppanen@hus.fi 5 Molecular Systems Biology Group, Institute of Biotechnology, University of Helsinki, 00790 Helsinki, Finland; salla.keskitalo@helsinki.fi (S.K.); markku.varjosalo@helsinki.fi (M.V.) 6 Fimlab Laboratories, Pirkanmaa Hospital District, 33520 Tampere, Finland 7 HiLIFE Helsinki Institute of Life Sciences, Institute of Biotechnology, University of Helsinki, 00790 Helsinki, Finland Citation: Palmroth, M.; Viskari, H.; 8 Centre for Rheumatic Diseases, Tampere University Hospital, 33520 Tampere, Finland Seppänen, M.R.J.; Keskitalo, S.; * Correspondence: pia.isomaki@tuni.fi Virtanen, A.; Varjosalo, M.; Silvennoinen, O.; Isomäki, P. IRF2BP2 Abstract: Interferon regulatory factor 2 binding protein 2 (IRF2BP2) is a transcriptional coregulator Mutation Is Associated with that has an important role in the regulation of the immune response. IRF2BP2 has been associated Increased STAT1 and STAT5 with the Janus kinase (JAK)—signal transducers and activators of transcription (STAT) pathway, but Activation in Two Family Members its exact role remains elusive.
    [Show full text]